Contrary to the fact that under normal conditions, IL-6 assures neuroprotection, neurogenesis, reactive astrogliosis, and B cell maturation [1], increased levels of circulating IL-6 were established in oncogenic diseases (e.g., malignant melanoma, gastrointestinal tumors, and lung cancer), associated with tumor extent, stage, or development [1]. This evidence concerns the gene IL6 and lung cancer.